UPDATE: Synergy Pharma (SGYP) Higher on Linzess Approval (IRWD) (FRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
FDA Approves IBS-C Treatment Linzess (IRWD) (FRX)
August 30, 2012 11:05 AM EDTBelow is the FDA press release related to approval of Ironwood Pharmaceuticals' (NASDAQ: IRWD) and Forest Labs' (NYSE: FRX) Linzess:
Press Release:
The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.
According to the National Institutes of Health, an estimated 63 million people are affected by chronic constipation. Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and do not respond to standard... More
UPDATE: Ironwood (IRWD), Forest (FRX) Win FDA Approval for Linzess
August 30, 2012 10:58 AM EDT(Updated - August 30, 2012 10:59 AM EDT)
Ironwood Pharmaceuticals (NASDAQ: IRWD), Forest Labs (NYSE: FRX) win FDA approval for Linzess to treat irritable bowel. (NOTE: Shares of IRWD were halted)... More
